What is the EV/EBITDA ratio for Roche Holding AG (RHHBY)?

The EV/EBITDA ratio for RHHBY stock is 14.21x.

Roche Holding (RHHBY) EV/EBITDA: History & Chart

Compare

Roche Holding AG(RHHBY)

Drug Manufacturers - General · Basel, BS

$56.39-0.50 (-0.88%)

Delayed quote: Aug 27, 2026, 4:00 PM EDT

Compare

About Roche Holding AG

Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.

Basel, BS

103,249 employees

www.roche.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Thomas Schinecker

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Roche Holding AG (RHHBY)	$359.46B	14.21x	N/A	N/A	N/A
UnitedHealth Group Incorporated (UNH)vs ›	$358.76B	15.51x	13.67x	13.77x	15.18x
Merck & Co., Inc. (MRK)vs ›	$369.34B	24.06x	11.60x	19.43x	18.06x
AbbVie Inc. (ABBV)vs ›	$455.87B	19.77x	21.96x	19.11x	16.38x
AstraZeneca PLC (AZN)vs ›	$255.15B	14.10x	16.48x	16.94x	20.64x
Amgen Inc. (AMGN)vs ›	$235.85B	18.75x	15.40x	16.29x	15.13x
Thermo Fisher Scientific Inc. (TMO)vs ›	$234.38B	25.95x	21.89x	21.64x	20.90x
Novo Nordisk A/S (NVO)vs ›	$205.42B	8.54x	9.56x	20.40x	22.43x
Abbott Laboratories (ABT)vs ›	$193.04B	20.79x	19.23x	20.63x	19.24x
Gilead Sciences, Inc. (GILD)vs ›	$184.82B	12.72x	13.89x	18.50x	15.50x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Roche Holding AG (RHHBY)

$359.46B

14.21x

N/A

UnitedHealth Group Incorporated (UNH)vs ›

$358.76B

15.51x

13.67x

13.77x

15.18x

Merck & Co., Inc. (MRK)vs ›

$369.34B

24.06x

11.60x

19.43x

18.06x

AbbVie Inc. (ABBV)vs ›

$455.87B

19.77x

21.96x

19.11x

16.38x

AstraZeneca PLC (AZN)vs ›

$255.15B

14.10x

16.48x

16.94x

20.64x

Amgen Inc. (AMGN)vs ›

$235.85B

18.75x

15.40x

16.29x

15.13x

Thermo Fisher Scientific Inc. (TMO)vs ›

$234.38B

25.95x

21.89x

21.64x

20.90x

Novo Nordisk A/S (NVO)vs ›

$205.42B

8.54x

9.56x

20.40x

22.43x

Abbott Laboratories (ABT)vs ›

$193.04B

20.79x

19.23x

20.63x

19.24x

Gilead Sciences, Inc. (GILD)vs ›

$184.82B

12.72x

13.89x

18.50x

15.50x

EV/EBITDA Ratio: 14.21x

RHHBY EV/EBITDA Ratio Metrics

RHHBY Competitors' EV/EBITDA Ratio

EV/EBITDA Ratio Formula & Definition

EV/EBITDA Ratio FAQ

Related Metrics